BioSpace News Archive

DermTech, Inc. announced the grant to one new employee of stock options to purchase an aggregate of 135,397 shares of the Company’s common stock at an exercise price of $6.35 per share and the grant to 28 new employees of restricted stock units representing the contingent right to receive up to an aggregate of 569,240 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan, or the 2022 Inducement Plan.

Neurelis, Inc., announced findings from a novel, investigational analysis of VALTOCO® (diazepam nasal spray) CIV.

Aquestive Therapeutics, Inc. announced that the management team will participate in the JMP Securities Life Sciences Conference from June 15th to June 16th.

Freenome, a privately held biotech company, presented findings at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting that demonstrate the clinical utility of detecting not just colorectal cancer (CRC), but also precancerous adenomas in a Medicare-aged cohort for tests that screen for CRC and multi-cancer early detection (MCED) tests that include CRC.

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-Market™ technology platform, today announced that management will participate in a virtual fireside chat at the Oppenheimer 22nd Annual Consumer Conference on Tuesday, June 14, 2022.

Funding will support exploratory phase 2 proof-of-concept study in patients hospitalized for moderate to severe diabetic foot ulcer infection (DFI).

Massive Bio, Inc. and AdhereTech announced their partnership to provide advanced, data-driven digital health technology solutions.

Pharvaris today announced the presentation of its development program at the Kinin 2022 Conference, to be held June 5-8, 2022, in Annecy, France.

With compelling competition for its research grant, the PMD Foundation is pleased to announce the unprecedented funding of two research projects totaling $200,000.

IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company’s Real World Solutions (RWS) business, effective July 7, 2022.